Allergan Restasis approval
This article was originally published in Pharmaceutical Approvals Monthly
Allergan's Restasis (cyclosporine ophthalmic emulsion 0.5%) clears FDA Dec. 23 for treatment of keratoconjunctivitis sicca (chronic dry eyes) after a protracted review. The original Feb. 24, 1999 NDA was granted priority status, but review was complicated by a unanimous advisory committee vote against approval in July 1999 and three "approvable" letters. In the NDA's four studies comparing Restasis to vehicle in 1,200 patients, a statistically significant increase in Schirmer wetting at six months was seen in 15% of Restasis patients. The agent will be available in early Apri
You may also be interested in...
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.